Zai Lab Ltd- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Zai Lab Ltd 公司

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

Zai Lab Ltd简介



公司代码ZLAB

公司名称Zai Lab Ltd

上市日期Sep 28, 2020

CEODu (Ying)

员工数量1869

证券类型Depository Receipt

年结日Sep 28

公司地址Building B, 899 Halei Road, Pudong

城市SHANGHAI

上市交易所NASDAQ OMX - NASDAQ BASIC

国家China

邮编201203

电话862161632588

网址https://www.zailaboratory.com/

公司代码ZLAB

上市日期Sep 28, 2020

CEODu (Ying)

Zai Lab Ltd公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Joshua L. Smiley

President, Chief Operating Officer

117.60K

+22.60%

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+10.86%

Mr. William David (Bill) Lis

Independent Director

35.11K

-8.50%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

19.15K

-4.46%

Dr. Ying (Samantha) Du, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

Mr. Peter Karl Wirth, J.D.

Independent Director

--

Mr. Leon Oliver (Lonnie) Moulder, Jr.

Independent Director

--

Mr. Frazor Titus Edmondson, J.D.

Company Secretary, Chief Legal Officer

--

Mr. Scott W. Morrison, CPA

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Joshua L. Smiley

President, Chief Operating Officer

117.60K

+22.60%

Dr. John David Diekman, Ph.D.

Lead Independent Director

99.77K

+10.86%

Mr. William David (Bill) Lis

Independent Director

35.11K

-8.50%

Dr. Yajing Chen, Ph.D.

Chief Financial Officer

19.15K

-4.46%

Dr. Ying (Samantha) Du, Ph.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

--

Ms. Leung (Nisa Bernice) Wing-Yu

Independent Director

--

收入明细

单位: USD更新时间: 4月6日周一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

业务USD

名称

营收

占比

ZEJULA

189.04M

41.35%

VYVGART

94.20M

20.60%

NUZYRA

60.84M

13.31%

Optune

48.33M

10.57%

QINLOCK

35.61M

7.79%

其他

29.17M

6.38%

地区USD

名称

营收

占比

China (Mainland)

460.16M

0.00%

业务

地区

业务USD

名称

营收

占比

ZEJULA

189.04M

41.35%

VYVGART

94.20M

20.60%

NUZYRA

60.84M

13.31%

Optune

48.33M

10.57%

QINLOCK

35.61M

7.79%

其他

29.17M

6.38%

股东统计

更新时间: 5月14日周四

持股股东

股东类型

持股股东

占比

RTW Investments L.P.

6.19%

RA Capital Management, LP

5.11%

Norges Bank Investment Management (NBIM)

3.42%

Frazier Life Sciences Management, L.P.

1.69%

ClearBridge Investments, LLC

1.61%

其他

81.97%

持股股东

占比

RTW Investments L.P.

6.19%

RA Capital Management, LP

5.11%

Norges Bank Investment Management (NBIM)

3.42%

Frazier Life Sciences Management, L.P.

1.69%

ClearBridge Investments, LLC

1.61%

其他

81.97%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

11.71%

Investment Advisor

5.60%

Venture Capital

5.36%

Hedge Fund

4.22%

Sovereign Wealth Fund

3.42%

Individual Investor

1.91%

Private Equity

1.69%

Research Firm

1.50%

Pension Fund

0.05%

其他

64.54%

机构持股



更新时间: 4月1日周三

报告期

机构数

持股数

持股占比

持股变动

2026Q4

280

37.42M

42.38%

--

2026Q1

352

37.82M

33.67%

-10.78M

2025Q4

370

44.73M

39.84%

-12.84M

2025Q3

372

46.61M

41.70%

-15.37M

2025Q2

394

60.58M

54.15%

-11.96M

2025Q1

453

59.51M

53.68%

-14.18M

2024Q4

446

60.80M

55.47%

-4.29M

2024Q3

439

51.45M

51.99%

-10.14M

2024Q2

454

47.04M

47.66%

-14.67M

2024Q1

465

46.22M

46.47%

-13.77M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RTW Investments L.P.

6.96M

6.14%

+4.67M

+203.71%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

3.84M

3.39%

+3.84M

--

Dec 31, 2025

Frazier Life Sciences Management, L.P.

1.90M

1.68%

+275.00K

+16.90%

Dec 31, 2025

ClearBridge Investments, LLC

1.81M

1.59%

-1.71M

-48.63%

Dec 31, 2025

Citadel Advisors LLC

1.69M

1.49%

+700.80K

+71.00%

Dec 31, 2025

Fidelity Management & Research Company LLC

1.44M

1.27%

-2.84M

-66.32%

Dec 31, 2025

Baron Capital Management, Inc.

1.42M

1.25%

+46.76K

+3.41%

Dec 31, 2025

Adar1 Capital Management LLC

1.25M

1.1%

+377.74K

+43.48%

Dec 31, 2025

Du (Ying Samantha)

1.06M

0.94%

+145.74K

+15.88%

Mar 11, 2026

持股ETF



更新时间: 12月6日周六

机构名称

占比

Tema Oncology ETF

1.67%

ALPS Medical Breakthroughs ETF

1.19%

Virtus LifeSci Biotech Products ETF

0.97%

Invesco Golden Dragon China ETF

0.58%

National Security Emerging Markets Index ETF

0.39%

iShares Biotechnology ETF

0.18%

Capital Group New Geography Equity ETF

0.15%

ProShares Ultra Nasdaq Biotechnology

0.12%

Invesco Nasdaq Biotechnology ETF

0.12%

ActivePassive International Equity ETF

0.03%

Tema Oncology ETF

占比1.67%

ALPS Medical Breakthroughs ETF

占比1.19%

Virtus LifeSci Biotech Products ETF

占比0.97%

Invesco Golden Dragon China ETF

占比0.58%

National Security Emerging Markets Index ETF

占比0.39%

iShares Biotechnology ETF

占比0.18%

Capital Group New Geography Equity ETF

占比0.15%

ProShares Ultra Nasdaq Biotechnology

占比0.12%

Invesco Nasdaq Biotechnology ETF

占比0.12%

ActivePassive International Equity ETF

占比0.03%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据